List of Excipients in Branded Drug METROGEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	BETADEX
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	EDETATE DISODIUM
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	METHYLPARABEN
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	NIACINAMIDE
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	PHENOXYETHANOL
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	PROPYLENE GLYCOL
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	PROPYLPARABEN

METROGEL Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

METROGEL is a brand family based on topical or vaginal metronidazole gel. Its commercial opportunity is primarily in differentiated generic formulations, improved skin tolerability, preservative systems, packaging, and indication-specific delivery rather than in new chemical-entity exclusivity. The core formulation is relatively simple: metronidazole in a water-based, carbomer-thickened gel with propylene glycol, a chelating agent, preservative, and pH adjustment system. Generic competition has reduced the value of the legacy brand, but formulation and device improvements can still support niche products, private-label supply, and lifecycle extensions.

What is METROGEL and which formulations are commercially relevant?

METROGEL refers to multiple metronidazole gel products. The two principal formulation categories are:

Product category	Active ingredient	Typical strength	Main indication	Route
METROGEL topical	Metronidazole	1%	Inflammatory lesions of rosacea	Cutaneous
Metronidazole topical gel, generic	Metronidazole	0.75% or 1%	Rosacea and related dermatologic uses, depending on label	Cutaneous
METROGEL-VAGINAL	Metronidazole	0.75%, 7.5 mg/g	Bacterial vaginosis	Vaginal
Metronidazole vaginal gel, generic	Metronidazole	0.75%	Bacterial vaginosis	Vaginal

The commercial and regulatory analysis must keep topical and vaginal products separate. They have different administration sites, microbial and preservative considerations, labeling requirements, packaging needs, and tolerability expectations.

Topical METROGEL is an established dermatology product. The active ingredient is generic metronidazole, and the principal competitive variables are vehicle performance, cosmetic acceptability, dosing convenience, pharmacy access, and price.

Vaginal metronidazole gel is an anti-infective product with a different value proposition. Applicator design, dose accuracy, leakage, messiness, treatment adherence, and vaginal tolerability create more meaningful opportunities for product differentiation.

What excipients are used in METROGEL formulations?

The FDA labeling for metronidazole topical and vaginal gels identifies a conventional aqueous carbomer gel system. Common excipients include:

Excipient or functional component	Primary formulation function	Commercial relevance
Purified water	Continuous vehicle	Low-cost, familiar, scalable
Carbomer	Gel former and rheology modifier	Controls viscosity, spreadability, and residence
Propylene glycol	Humectant, solvent, and skin-feel modifier	Can improve wetting but may affect irritation
Disodium edetate	Chelating agent	Supports preservative performance and chemical stability
Methylparaben	Antimicrobial preservative	Effective but subject to consumer and regulatory preferences
Sodium hydroxide	Neutralization and pH adjustment	Controls carbomer viscosity and product pH
Metronidazole	Active pharmaceutical ingredient	Antibacterial and anti-inflammatory active

The exact carbomer grade and levels can differ across products. Carbomer selection affects yield stress, extrusion force, spreadability, phase behavior, and sensory profile. A formulation that is technically equivalent in assay and viscosity may still perform differently during application.

For topical use, the target profile is usually a non-greasy gel that spreads quickly, does not pill under sunscreen or cosmetics, and produces limited tack after drying. For vaginal use, the formulation must balance residence time with acceptable leakage and applicator performance.

How does the excipient strategy affect METROGEL performance?

Carbomer selection and rheology

Carbomer is the main platform excipient in the conventional gel. Its neutralization state and concentration determine viscosity and yield behavior. A highly structured gel may improve local residence but can increase extrusion force and leave a heavy residue. A lower-viscosity system may improve spreading but increase run-off or leakage.

Key development variables include:

• Apparent viscosity across clinically relevant shear rates
• Yield stress
• Thixotropic recovery
• Extrusion force through the commercial package
• Spread diameter under controlled pressure
• Dry-down time
• Residual tack
• Compatibility with pumps, tubes, and vaginal applicators

A differentiated manufacturer can optimize the rheology profile rather than simply match a single viscosity value.

Propylene glycol and skin tolerability

Propylene glycol can function as a humectant and co-solvent. It also contributes to skin feel and active distribution. Excessive use may increase stinging or irritation in sensitive skin, particularly in rosacea patients with impaired barrier function.

A lower-irritancy vehicle can support a premium generic position. Potential approaches include reducing propylene glycol concentration, replacing part of the solvent system with a less irritating co-solvent, or using a polymer and humectant combination that maintains metronidazole uniformity without increasing solvent load.

Any change must be assessed against drug release, preservative performance, viscosity, microbial limits, and in-use stability.

Preservative selection

Methylparaben is present in legacy metronidazole gel formulations. A preservative strategy has several commercial implications:

• Preservative-containing multidose packaging is simple and familiar.
• Preservative-free packaging can improve positioning for sensitive-skin consumers.
• Pump delivery can reduce repeated environmental exposure compared with open-mouth tubes.
• Alternative preservatives may create new irritation or compatibility concerns.
• A preservative change can trigger comparative microbiological and stability work.

A preservative-free topical gel would require a package and manufacturing process designed to control microbial risk. Airless pumps, unit-dose sachets, and tightly controlled filling systems are potential options, but each increases packaging cost.

pH adjustment and active stability

Sodium hydroxide is used to neutralize the carbomer and establish the final gel structure. pH affects viscosity, metronidazole solubility, preservative effectiveness, and skin or vaginal tolerability.

A formulation program should evaluate:

• Metronidazole assay and degradation products
• pH drift during shelf life
• Viscosity drift
• Carbomer-polymer interaction
• Preservative efficacy
• Container closure compatibility
• Performance after repeated dispensing

The practical opportunity is to define a robust operating range rather than pursue a single nominal pH.

What formulation patents could protect a new METROGEL product?

The active ingredient is old and broadly available. A new product therefore requires protection around the formulation, delivery system, manufacturing process, or clinical use.

Potential claim categories include:

Low-irritancy topical gel

Claims could focus on a defined combination of:

• Metronidazole concentration
• Carbomer grade and concentration
• Reduced propylene glycol content
• Defined pH range
• Preservative system
• Viscosity or yield-stress parameters
• Improved tolerability or reduced stinging

Patent strength depends on whether the composition produces an unexpected technical effect, not simply whether it uses a different excipient percentage.

Cosmetic-compatible rosacea gel

A product can target patients who apply sunscreen, moisturizer, or makeup over the medicine. Relevant technical features may include rapid drying, reduced pilling, low tack, low residue, and compatibility with common cosmetic products.

A patent based only on subjective cosmetic preference may be weak. Objective test methods, defined polymer systems, and comparative performance data can improve enforceability.

Preservative-free or low-preservative system

A preservative-free multidose gel can support a differentiated product if the package and manufacturing process provide adequate microbial control. Possible claim elements include:

• Airless pump or one-way dispensing system
• Unit-dose container
• Defined water activity
• Specific container closure system
• Microbiological acceptance criteria
• Stability after simulated consumer use

The intellectual-property strategy should treat the formulation and package as a combined system.

Vaginal residence and applicator technology

For metronidazole vaginal gel, protection may focus on:

• Reduced leakage
• Controlled residence time
• Low-mess delivery
• Dose metering
• Applicator geometry
• Unit-dose packaging
• Applicator materials compatible with the formulation

A vaginal product with improved administration could compete on adherence and convenience even when the drug and strength remain unchanged.

When does METROGEL lose exclusivity?

METROGEL does not have biologic exclusivity and does not require biosimilar analysis. Metronidazole is a small molecule that can be copied through the abbreviated new drug application pathway if a generic applicant meets FDA requirements.

The relevant exclusivity barriers are:

Barrier	Relevance to METROGEL
Active-ingredient exclusivity	Not commercially meaningful for old metronidazole products
New-drug exclusivity	Depends on the specific NDA and approval history
Formulation patents	May delay or shape generic entry if listed and enforceable
Method-of-use patents	May matter for a specifically claimed indication
Device or packaging patents	Can protect differentiated delivery but usually do not block all gel competition
Regulatory exclusivity	Must be confirmed for the specific NDA and product
Trade secrets	May protect manufacturing know-how but do not prevent independent development

Patent expiration cannot be assigned reliably to "METROGEL" as a single product because the brand name covers different NDAs, strengths, routes, formulations, and marketing histories. Orange Book status also depends on the specific listed drug and current FDA publication.

What is the Orange Book and Paragraph IV risk for METROGEL?

For an approved small-molecule drug, generic applicants may file an ANDA with patent certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed.

For metronidazole gel, the commercial risk is generally greater for formulation and use patents than for the active ingredient itself. A generic applicant may seek approval by:

• Matching the reference formulation closely
• Designing around listed formulation claims
• Challenging listed patents under Paragraph IV
• Filing a Paragraph III certification for later entry
• Relying on patent expiry where no enforceable barrier remains

A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman framework. A timely suit may create a statutory stay of FDA approval, generally up to 30 months, subject to statutory exceptions and litigation developments. The existence of a listed patent does not establish that it will block entry.

For commercial diligence, the relevant questions are:

1. Which exact NDA is the reference listed drug?
2. Which patents are currently listed for that NDA?
3. Do the patents claim the composition, method of use, or delivery system?
4. Are the claims broad enough to cover a standard carbomer gel?
5. Are the patents near expiration?
6. Has a generic applicant made a Paragraph IV filing?
7. Has the sponsor settled or licensed entry?

Which companies are challenging or competing with METROGEL?

Competition occurs across several groups:

Generic pharmaceutical manufacturers

Generic companies can compete with metronidazole topical and vaginal gels through lower pricing, wholesaler access, and pharmacy substitution. The main competitive advantage is cost rather than technical differentiation.

Branded dermatology companies

Branded competitors in rosacea include other topical agents and delivery platforms, such as ivermectin cream, azelaic acid products, brimonidine gel, oxymetazoline cream, and newer fixed or combination approaches. These products compete for the same dermatology prescribing budget but do not necessarily use the same mechanism.

Compounded pharmacies

Compounding can create local alternatives, particularly where commercial products are unavailable or patients require customized vehicles. Compounded products generally lack the same FDA-approved commercial pathway and standardized manufacturing controls as approved products.

Contract manufacturers and private-label suppliers

A manufacturer with validated metronidazole gel technology can supply health-system, retail, specialty, or international private-label customers. The value proposition is reliable quality, scalable filling, and a formulation that meets regional regulatory requirements.

What commercial opportunities exist for METROGEL excipient innovation?

Premium generic rosacea gel

A manufacturer can position a topical product around:

• Lower sting and irritation
• Better cosmetic layering
• Faster drying
• Lower tack
• Improved pump delivery
• Preservative reduction
• Smaller or more convenient package formats

The reimbursement environment may limit premium pricing, but a superior patient experience can improve pharmacy pull-through and prescriber preference.

OTC-adjacent skincare positioning

Metronidazole remains a prescription active. A company cannot market it as an over-the-counter rosacea product without FDA approval under an appropriate regulatory pathway. Commercial opportunities can still exist in adjacent non-drug skincare products, provided they do not make drug claims or improperly imply treatment of rosacea.

Vaginal delivery improvements

A less messy, easier-to-administer vaginal gel can address patient complaints that are not solved by changing the active ingredient. Opportunities include:

• Pre-filled applicators
• Lower-leakage gel rheology
• Unit-dose packaging
• Applicators with reduced residual volume
• Improved disposal systems
• Packaging suitable for telehealth and direct-to-patient fulfillment

International product development

Metronidazole gel is widely recognized across global markets, but regulatory requirements, approved indications, excipient permissions, preservative rules, and packaging standards differ. A platform formulation may support multiple markets if the company designs the development program around regional excipient acceptance and stability requirements.

Manufacturing and supply-chain advantages

Manufacturing know-how can create a practical barrier even where composition patents are weak. Important capabilities include:

• Consistent carbomer hydration
• Controlled neutralization
• Low-shear active incorporation
• Deaeration
• Uniform filling
• Tube and pump compatibility
• Microbial control
• Long-term viscosity stability

A robust process can reduce batch failures and support contract manufacturing revenue.

How strong is the patent estate for METROGEL?

The legacy metronidazole composition is unlikely to provide a strong standalone exclusivity position because metronidazole and conventional gel excipients are well established. Patent strength is more likely to arise from a narrow technical combination or delivery system.

IP category	Expected strategic value	Main vulnerability
Metronidazole molecule	Low	Expired or broadly available
Conventional carbomer gel	Low to moderate	Prior art and design-around options
Defined low-irritancy formulation	Moderate	Requires strong comparative evidence
Preservative-free package	Moderate	May be protected as device or system claims
Vaginal applicator design	Moderate	Competitors can use alternative devices
Manufacturing process	Moderate	Trade-secret protection may be stronger than patent protection
Method-of-use claims	Variable	Limited by claim scope and indication
Combination formulation	Potentially high	Depends on unexpected results and claim breadth

The strongest portfolio would combine composition claims, package or device claims, manufacturing claims, and method-of-use claims. A single narrow formulation patent is less durable because competitors can modify polymer grade, solvent ratio, preservative, or package.

How does METROGEL compare with competing rosacea products?

Product class	Main differentiation	Excipient opportunity
Metronidazole gel	Familiar active, low-cost generic	Better tolerability, cosmetics, dispensing
Ivermectin cream	Cream vehicle and anti-inflammatory positioning	Emulsion stability, skin feel, barrier support
Azelaic acid gel or foam	Different active and vehicle	Reduced sting, improved spreadability
Brimonidine gel	Vasoconstrictor for erythema	Rapid application and residue control
Oxymetazoline cream	Erythema reduction	Emulsion and package performance
Combination products	Multiple therapeutic mechanisms	Compatibility, stability, and dosing convenience

METROGEL is most vulnerable where prescribers prioritize visible erythema control, cosmetic acceptability, or once-daily convenience over established low-cost anti-inflammatory treatment.

What regulatory strategy applies to a new metronidazole gel?

A conventional generic product would generally proceed through the ANDA pathway if it can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA guidance and product-specific requirements.

A materially different formulation may require a 505(b)(2) NDA rather than an ANDA, particularly if it introduces a new delivery system, formulation, route-related attribute, or clinical benefit that cannot be supported solely through generic equivalence.

Regulatory development should address:

• Identity, strength, quality, and purity
• Comparative composition
• In vitro release or permeation, where applicable
• Rheology and physical characterization
• Microbial limits and preservative effectiveness
• Container-closure integrity
• Stability under ICH conditions
• In-use and shipping stability
• Applicator dose delivery for vaginal products
• Labeling and indication-specific clinical requirements

A 505(b)(2) strategy can create a more defensible commercial product but carries greater clinical, regulatory, and development cost than a conventional ANDA.

Key Takeaways

• METROGEL is a metronidazole gel product family, principally covering topical rosacea and vaginal bacterial-vaginosis formulations.
• The core excipient system uses water, carbomer, propylene glycol, disodium edetate, methylparaben, and sodium hydroxide.
• The best formulation opportunities involve tolerability, cosmetic compatibility, preservative reduction, rheology, packaging, and applicator performance.
• The active ingredient does not provide a meaningful new-chemical-entity barrier.
• Patent value is more likely to arise from defined formulation combinations, delivery systems, manufacturing processes, and method-of-use claims.
• Generic entry risk is high for conventional metronidazole gels unless enforceable formulation or device patents remain.
• Vaginal products offer greater room for meaningful differentiation through leakage control, dose delivery, and patient convenience.
• A conventional copy is best suited to an ANDA strategy. A materially improved delivery system may support a 505(b)(2) pathway.
• Commercial success depends on manufacturing consistency, pharmacy access, package performance, and a clear reason for prescribers or patients to choose the product over low-cost generics.

FAQs

Is METROGEL a biologic that could face biosimilar competition?

No. METROGEL contains metronidazole, a small-molecule active ingredient. Competition occurs through generic drug applications, not biosimilar applications.

Can a new company patent a metronidazole gel?

Yes, but a patent would generally need to claim a novel and non-obvious formulation, delivery system, manufacturing process, or method of use. The metronidazole active ingredient and basic aqueous carbomer gel platform are established technologies.

Is a preservative-free METROGEL product commercially feasible?

Yes, but it requires a microbial-control strategy involving packaging, manufacturing, stability, and in-use testing. Unit-dose and airless-pump systems are the most obvious commercial approaches.

Would a better applicator support a new regulatory exclusivity strategy?

Potentially. A materially improved applicator may support device or formulation claims and, depending on the product differences and regulatory strategy, may be relevant to a 505(b)(2) application. It would not automatically block all generic gel products.

Which METROGEL product has the greater formulation opportunity?

The vaginal product generally offers greater room for practical differentiation because leakage, applicator handling, dose accuracy, and treatment messiness directly affect adherence. Topical rosacea products offer a larger opportunity in cosmetic compatibility and low-irritancy skin feel.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Metronidazole topical gel prescribing information. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). DailyMed: Metronidazole vaginal gel prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2017). Bioequivalence studies with topical dermatological drug products submitted in ANDAs: Guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2013). Regulatory classification of pharmaceutical co-crystals: Guidance for industry. U.S. Department of Health and Human Services.

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.